Immune checkpoint inhibitors for multiple myeloma immunotherapy

被引:13
|
作者
Liu, Zhaoyun [1 ]
Xu, Xintong [1 ]
Liu, Hui [1 ]
Zhao, Xianghong [1 ]
Yang, Chun [1 ]
Fu, Rong [1 ]
机构
[1] Tianjin Med Univ, Gen Hosp, Dept Hematol, Tianjin 300052, Peoples R China
基金
中国国家自然科学基金;
关键词
Immune checkpoint; CTLA-4; TIGIT; Multiple myeloma; treatment strategy; T-LYMPHOCYTE ATTENUATOR; KIR ANTIBODY IPH2101; PHASE-I TRIAL; PD-1; BLOCKADE; DARATUMUMAB MONOTHERAPY; ANTITUMOR IMMUNITY; B-LYMPHOCYTE; PLASMA-CELLS; EXPRESSION; CANCER;
D O I
10.1186/s40164-023-00456-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Multiple myeloma (MM) is related to immune disorders, recent studys have revealed that immunotherapy can greatly benefit MM patients. Immune checkpoints can negatively modulate the immune system and are closely associated with immune escape. Immune checkpoint-related therapy has attracted much attention and research in MM. However, the efficacy of those therapies need further improvements. There need more thoughts about the immune checkpoint to translate their use in clinical work. In our review, we aggregated the currently known immune checkpoints and their corresponding ligands, further more we propose various ways of potential translation applying treatment based on immune checkpoints for MM patients.
引用
收藏
页数:20
相关论文
共 50 条
  • [31] Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer
    Mónica Cejuela
    Andrea Vethencourt
    Sonia Pernas
    Current Oncology Reports, 2022, 24 : 1801 - 1819
  • [32] Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy
    Marquez-Garban, Diana C.
    Deng, Gang
    Comin-Anduix, Begonya
    Garcia, Alejandro J.
    Xing, Yanpeng
    Chen, Hsiao-Wang
    Cheung-Lau, Gardenia
    Hamilton, Nalo
    Jung, Michael E.
    Pietras, Richard J.
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2019, 193
  • [33] Targeting Immune Suppressive Microenvironment By Immune Checkpoint Blockade in Multiple Myeloma
    Gorgun, Gullu Topal
    Cowens, Kristen
    Paula, Steven
    Samur, Mehmet Kemal
    Ohguchi, Hiroto
    Singh, Ahaana
    White, Randie E.
    Bianchi, Giada
    Suzuki, Rikio
    Kikuchi, Shohei
    Harada, Takeshi
    Mimura, Naoya
    Tai, Yu-Tzu
    Hideshima, Teru
    Laubach, Jacob P.
    Raje, Noopur
    Munshi, Nikhil C.
    Richardson, Paul G.
    Anderson, Kenneth C.
    BLOOD, 2014, 124 (21)
  • [34] Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy
    Nakajima, Hiromichi
    Nakatsura, Tetsuya
    IMMUNOLOGICAL MEDICINE, 2021, 44 (01) : 10 - 15
  • [35] Dermatologic Reactions to Immune Checkpoint Inhibitors Skin Toxicities and Immunotherapy
    Sibaud, Vincent
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2018, 19 (03) : 345 - 361
  • [36] Immunotherapy Based on Immune Checkpoint Molecules and Immune Checkpoint Inhibitors in Gastric Cancer-Narrative Review
    Poniewierska-Baran, Agata
    Sobolak, Karolina
    Niedzwiedzka-Rystwej, Paulina
    Plewa, Paulina
    Pawlik, Andrzej
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (12)
  • [37] Immunotherapy (Checkpoint Inhibitors)
    Reck, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S117 - S117
  • [38] The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study
    Suen, H.
    Brown, R.
    Yang, S.
    Ho, P. J.
    Gibson, J.
    Joshua, D.
    LEUKEMIA, 2015, 29 (07) : 1621 - 1622
  • [39] The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study
    H Suen
    R Brown
    S Yang
    P J Ho
    J Gibson
    D Joshua
    Leukemia, 2015, 29 : 1621 - 1622
  • [40] Checkpoint Inhibitors in Multiple Myeloma: Intriguing Potential and Unfulfilled Promises
    Alkharabsheh, Omar
    Trisel, Zachary
    Badami, Sunil
    Aljama, Mohammed A.
    Sidiqi, M. Hasib
    CANCERS, 2022, 14 (01)